CoronaryAtlas logo
CoronaryAtlas
Copeptin
Pathway / Myocardial injury (shared endpoint)

Copeptin

AVPpeptide

Copeptin is released in response to myocardial ischemia and necrosis, providing early detection of acute coronary syndrome alongside cardiomyocyte injury.

Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencehigh
RationaleEarly neuroendocrine marker of cardiac injury and acute MI detection.
Also acts inSystemic / off-pathway
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000101200

Type I vs Type II discrimination

ScoresShared / rises in both
R — rupture / Type-I
67
C — confounder / Type-II
58
A — assay feasibility
84
E — evidence strength
42
T1DI (composite)
23
Specificity differential (R−C)+32.3
Direct evidence: higher in Type I (D=+2)
Copeptin levels were significantly elevated in T1MI compared to T2MI patients, supporting differentiation between the two MI types.
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
3hypovolemia / dehydrationmag 2
4tachyarrhythmian/a
5hypoxemia / respiratory failuren/a
6hypertensive emergencymag 1
7high-demand / peri-operative stressmag 2
Coverage: 4/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 19 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Automated sandwich immunofluorescent/immunoluminometric assay
Reagent / substrate
Anti-copeptin antibody pair (Thermo BRAHMS)
Platform
Kryptor/automated; some POC
Turnaround · availability
Rapid (~10–30 min) · CE-marked; US research/limited

Human genetic evidence

0.016
Open Targets association (STEMI)

Literature evidence(14)

Clinical trials(5)